Cov ntaub ntawv tseem ceeb ntawm Cov Tshuaj

Letrozole yog ib qho zoo heev thiab xaiv tsis yog -steroidal aromatase inhibitor. Los ntawm inhibiting estrogen synthesis, nws yog siv nyob rau hauv kev kho mob cancer ntawm lub mis, feem ntau yog adjuvant therapy rau postmenopausal hormone receptor- mob cancer mis zoo thiab nyob rau hauv kev kho mob cancer ntawm lub mis siab heev.

Raws li cov ntaub ntawv tshawb fawb los ntawm Grand View Research, lub lag luam thoob ntiaj teb cov tshuaj kho mob qog noj ntshav tau kwv yees kom ncav cuag $ 37.6 billion los ntawm 2025 thiab $ 45 billion txog $ 55 billion los ntawm 2030. Ntawm qhov no, aromatase inhibitors suav txog 38% ntawm lub ntiaj teb cov tshuaj mob qog noj ntshav mis, thiab Letrozole, raws li thawj - kab kev kho mob kev lag luam.

Nyob rau hauv xyoo tas los no, qhov xwm txheej ntawm mob qog noj ntshav hauv Suav teb tau nce ntxiv, thiab qhov kev thov rau Letrozole API (Cov Khoom Siv Tshuaj Muaj Zog) xav kom loj hlob tsis tu ncua. Lub caij no, Beijing Yiling Bioengineering Technology Co., Ltd., ib tug nkaus - cov tuam txhab xeeb ntxwv ntawm Tuam Txhab, tuav kev pom zoo rau Letrozole Tablets (kev npaj tshuaj). Raws li cov khoom lag luam suav nrog hauv National Volume-Kev Pabcuam Raws Li Kev Pabcuam (VBP), kev koom ua ke ntawm API thiab kev npaj tsim khoom rau Letrozole yuav tsum tau ua tiav xyoo no, uas yuav txhim kho kev lag luam kev sib tw ntawm API thiab kev npaj.

Tsis tas li ntawd, noj cov kev pom zoo hauv tsev raws li lub sijhawm, Lub Tuam Txhab yuav nrawm rau kev sau npe thoob ntiaj teb thiab kev muag khoom txawv teb chaws ntawm Letrozole API raws li nws cov phiaj xwm kev tsim kho txawv teb chaws, txuas ntxiv mus rau kev lag luam txawv teb chaws xws li Europe thiab Tebchaws Meskas.

Raws li tam sim no, Lub Tuam Txhab tau sau tag nrho R & D peev ntawm kwv yees li RMB 4.7 lab hauv Letrozole API, suav nrog cov txheej txheem xws li kev txhim kho txheej txheem, kev tshawb fawb zoo, kev tshawb fawb ruaj khov, thiab kev sau npe.